A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase‐III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing‐induced heart failure (Q51421591)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 25, 2011

Language	Label	Description	Also known as
English	A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase‐III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing‐induced heart failure	scientific article published on August 25, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

A new mechanism preventing proarrhythmia in chronic heart failure: rapid phase‐III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing‐induced heart failure (English)

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

0 references

chronic heart failure

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Günter Breithardt

8

object named as

Günter Breithardt

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

10

object named as

Lars Eckardt

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Gerrit Frommeyer

1

object named as

Gerrit Frommeyer

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

author name string

Peter Milberg

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Patricia Witte

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Jörg Stypmann

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Matthias Koopmann

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Martin Lücke

6

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Nani Osada

7

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Michael Fehr

9

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21873342

11 December 2024

publication date

25 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1093/eurjhf/hfr107

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21873342

11 December 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1093%2Feurjhf%2Fhfr107

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1093/eurjhf/hfr107

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

https://onlinelibrary.wiley.com/doi/full-xml/10.1093/eurjhf/hfr107

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

13

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

10

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

1060-1069

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

Arrhythmias in heart failure: current concepts of mechanisms and therapy

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Clinical significance and management of ventricular arrhythmias in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Is there a role for amiodarone in the era of the implantable cardioverter-defibrillator?

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Doppler echocardiography and tissue Doppler imaging in the healthy rabbit: differences of cardiac function during awake and anaesthetised examination

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Amiodarone-induced postrepolarization refractoriness suppresses induction of ventricular fibrillation

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Potassium channel down-regulation in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Cellular basis of triggered arrhythmias in heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Changes in connexin 43, metalloproteinase and tissue inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy in dogs

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Dronedarone in patients with congestive heart failure: insights from ATHENA.

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Increased mortality after dronedarone therapy for severe heart failure

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFR107

21 January 2018

Pacing-induced heart failure causes a reduction of delayed rectifier potassium currents along with decreases in calcium and transient outward currents in rabbit ventricle

4

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission

10

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes

16

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Taking the "idio" out of "idiosyncratic": predicting torsades de pointes

19

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic

21

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current

22

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts

25

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy

26

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Arrhythmogenic potential of positive inotropic agents

32

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence

35

1 reference

10.1093/EURJHF/HFR107

https://api.crossref.org/works/10.1093/EURJHF/HFR107

11 December 2024

Identifiers

10.1093/EURJHF/HFR107

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/21873342

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51421591&oldid=2285863865"